论文部分内容阅读
本文概述了148例再生障碍性贫血的临床和85例的疗效分析。从发病方面,148例住院病人占同期内科病人的0.35%和贫血病人的43.5%,说明再障并非罕见。症状方面有贫血、出血和感染者分别占97%、89%和70%,极大多数病人呈全血减少和骨髓增生不良。中医辨证:129例中属脾肾阳虚者99例和肝肾阴虚者30例。治疗分中西结合组(中药加丙睾),单独中药组,免疫抑制组和支持疗法组。中西结合组的高效率达23.8%,比单独中医组为好。免疫疗法组看来有一定的苗头,而支持疗法组效果最差,死亡率占43%。作者认为中西结合组具有肯定效果而副反应少,免疫抑制组应严格掌握适应症,在目前条件下尚不宜普遍使用。
This article provides an overview of the clinical efficacy of 148 patients with aplastic anemia and 85 patients. From the onset, 148 cases of hospitalized patients accounted for the same period 0.35% of patients and 43.5% of anemic patients, indicating that aplastic anemia is not uncommon. Symptoms of anemia, bleeding and infection accounted for 97%, 89% and 70%, the vast majority of patients showed whole blood decreased and poor bone marrow proliferation. TCM syndromes: 129 cases of spleen and kidney yang deficiency in 99 cases and liver and kidney yin in 30 cases. Treatment points in the Western combination group (Chinese medicine plus testosterone), separate Chinese medicine group, immunosuppressive group and supportive therapy group. The high efficiency of the combination of Chinese and Western groups reached 23.8%, better than the Chinese medicine group alone. The immunotherapy group appears to have some signs, while the supportive therapy group is the worst, with a 43% mortality rate. The authors believe that the combination of Chinese and Western has a positive effect with fewer side effects, immunosupression group should be strictly controlled indications, not currently under the conditions of universal use.